Castle Biosciences Inc (CSTL) stock
CSTLNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/303% below fair value
$33.79−0.71 (-2.06%)
Close on Nov 13, 2026Market cap $1.03BP/E –Yield 0.00%
Castle Biosciences gross margin
Gross margin is gross profit as a percentage of revenue.
Castle Biosciences's gross margin for the twelve months ending Sep 30, 2026 was 77.1%. For fiscal 2025 it was 79.4%, against 81.9% the year before. The highest annual figure on record is 85.9% in fiscal 2019.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 79.4% | −2.5 |
| FY2024 | Dec 31, 2024 | 81.9% | +2.3 |
| FY2023 | Dec 31, 2023 | 79.5% | +2.9 |
| FY2022 | Dec 31, 2022 | 76.6% | −6.5 |
| FY2021 | Dec 31, 2021 | 83.2% | −1.4 |
| FY2020 | Dec 31, 2020 | 84.5% | −1.4 |
| FY2019 | Dec 31, 2019 | 85.9% | +9.2 |
| FY2018 | Dec 31, 2018 | 76.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 76.8% | −0.7 |
| Q2 FY2026 | Jun 30, 2026 | 77.1% | −2.4 |
| Q1 FY2026 | Mar 31, 2026 | 75.5% | −5.9 |
| Q4 FY2025 | Dec 31, 2025 | 79.0% | −2.3 |
| Q3 FY2025 | Sep 30, 2025 | 77.5% | −4.3 |
| Q2 FY2025 | Jun 30, 2025 | 79.5% | −3.8 |
| Q1 FY2025 | Mar 31, 2025 | 81.4% | +0.4 |
| Q4 FY2024 | Dec 31, 2024 | 81.3% | +0.0 |
| Q3 FY2024 | Sep 30, 2024 | 81.8% | +0.2 |
| Q2 FY2024 | Jun 30, 2024 | 83.3% | +5.4 |
| Q1 FY2024 | Mar 31, 2024 | 81.0% | +5.2 |
| Q4 FY2023 | Dec 31, 2023 | 81.2% | +6.0 |
| Q3 FY2023 | Sep 30, 2023 | 81.6% | +5.5 |
| Q2 FY2023 | Jun 30, 2023 | 77.9% | +0.0 |
| Q1 FY2023 | Mar 31, 2023 | 75.8% | −2.1 |
| Q4 FY2022 | Dec 31, 2022 | 75.2% | −6.5 |
| Q3 FY2022 | Sep 30, 2022 | 76.1% | −4.8 |
| Q2 FY2022 | Jun 30, 2022 | 77.9% | −5.8 |
| Q1 FY2022 | Mar 31, 2022 | 77.9% | −8.9 |
| Q4 FY2021 | Dec 31, 2021 | 81.6% | −2.9 |
| Q3 FY2021 | Sep 30, 2021 | 80.8% | −2.9 |
| Q2 FY2021 | Jun 30, 2021 | 83.8% | +0.6 |
| Q1 FY2021 | Mar 31, 2021 | 86.7% | +0.5 |
| Q4 FY2020 | Dec 31, 2020 | 84.5% | −4.0 |
| Q3 FY2020 | Sep 30, 2020 | 83.7% | −4.7 |
| Q2 FY2020 | Jun 30, 2020 | 83.1% | +1.7 |
| Q1 FY2020 | Mar 31, 2020 | 86.3% | +4.6 |
| Q4 FY2019 | Dec 31, 2019 | 88.6% | +0.5 |
| Q3 FY2019 | Sep 30, 2019 | 88.4% | +24.8 |
| Q2 FY2019 | Jun 30, 2019 | 81.4% | +14.8 |
| Q1 FY2019 | Mar 31, 2019 | 81.7% | +15.9 |
| Q4 FY2018 | Dec 31, 2018 | 88.1% | – |
| Q3 FY2018 | Sep 30, 2018 | 63.6% | – |
| Q2 FY2018 | Jun 30, 2018 | 66.6% | – |
| Q1 FY2018 | Mar 31, 2018 | 65.8% | – |
See a number that looks wrong?